I. 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The applicant Shire Pharmaceutical Contracts Limited submitted on 26 March 2002 an application for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
through the centralised procedure for Xagrid, which was designated as an orphan medicinal product 
EU/3/00/010 on 29 December 2000.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr E. Abadie 
Co-Rapporteur:  Dr P. Neels 
Orphan Drugs: 
Anagrelide hydrochloride was designated as an orphan medicinal product in the following indication:  
treatment of essential thrombocythaemia. 
Scientific Advice: 
The applicant received Scientific Advice from the CPMP on 15 November 2001. The Scientific 
Advice pertained to part IV of the dossier.  
Licensing status: 
Xagrid has been given a Marketing Authorisation in Switzerland (December 1999) and Latvia 
(October 2003). Agrylin (tradename used outside of the EEA) has been given a Marketing 
Authorisation in the United States (March 1997), Canada (November 1997), Israel (July 1998), Korea 
(October 1999), Australia (November 1999), South Africa (October 2000), Brazil (August 2002), 
Taiwan (May 2003), Hong Kong (December 2003) and Singapore (March 2004).  
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 22 April 2002. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 
28 June 2002. The Co-Rapporteur's first Assessment Report was circulated to all CPMP 
members on 28 June 2002.  
During the meeting on 23 – 25 July 2002 the CPMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 26 July 2002. 
The company submitted the responses to the CPMP consolidated List of Questions on 
10 December 2002. 
The summary report of the inspection carried out at the manufacturing site Mallinckrodt Inc 
between 3-4 October 2002 of the MCA was issued on 20 November 2002.  
The final integrated report of the inspections carried out for study 700-014, at two clinical sites 
in the USA, between 15-17 October 2002 and 21-24 October 2002, was issued on 17 December 
2002. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 28 January 2003.  
During the CPMP meeting on 18 – 20 February 2003 the CPMP adopted a List of Outstanding 
Issues to be addressed by the applicant in writing and if necessary during an oral explanation. 
The List of Outstanding Issues was sent to the applicant on 21 February 2003.  
The  company  submitted  the  responses  to  the  CPMP  List  of  Outstanding  Issues  on  25  April 
2003. 
1/4 
EMEA 2004 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The  Rapporteur  circulated  the  Rapporteurs’  Joint  Review  on  the  company’s  responses  to  the 
List of Outstanding Issues to all CPMP members on 12 May 2003.  
During  the  CPMP  meeting  on  20  –  22  May  2003  the  CPMP  adopted  a  List  of  Outstanding 
Issues to be addressed by the applicant in writing and if necessary during an oral explanation. 
The List of Outstanding Issues was sent to the applicant on 23 May 2003.  
The company submitted the responses to the CPMP List of Outstanding Issues on 4 June 2003. 
The  Rapporteur  circulated  the  Rapporteurs’  Joint  Review  on  the  company’s  responses  to  the 
List of Outstanding Issues to all CPMP members on 16 June 2003.  
During  the  CPMP  meeting  on  24  –  26  June  2003,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP on 24 June 2003. 
During the meeting on 22 – 24 July 2003 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation under exceptional circumstances to Xagrid on 24 July 2003.  
The post-marketing commitments agreed as part of the CPMP Opinion on 24 July 2003 had 
included a specific obligation to provide efficacy and safety data from an ongoing UK Medical 
Research Counciltrial in patients with essential thrombocythaemia. In September 2003, Shire 
informed the CPMP that the anagrelide plus aspirin arm of the MRC trial had been 
discontinued. The issue was discussed by the CPMP during its meeting on 23-25 September 
2003.  
The European Commission, at the request of the EMEA, put the Standing Committee phase on 
hold  pending  the  outcome  of  the  CPMP  discussion  regarding  thediscontinuation  of  the 
anagrelide plus aspirin arm of the study.  
During the CPMP meeting on 23-25 September, oral explanations were given by the applicant 
on 23 September 2003. 
During the CPMP meeting on 23-25 September the CPMP adopted a List of Questions to be 
addressed by the applicant in writing. The List of Questions was sent to the applicant on 25 
September 2003.    
The company submitted the responses to the CPMP List of Questions on 5 December 2003. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 2 February 2004.  
During the meeting on 24– 26 February 2004 the CPMP adopted a List of Outstanding Issues to 
be addressed by the applicant in writing and if necessary during an oral explanation. The List of 
Outstanding Issues was sent to the applicant on 27 February 2004.  
The company submitted the responses to the CPMP List of Outstanding Issues on 12 March 
2004. 
The Rapporteur circulated the Rapporteurs’ Joint Review on the company’s responses to the 
CPMP List of Outstanding Issues to all CPMP members on 9 April 2004. 
During the meeting on 20 – 22 April 2004 the CPMP adopted a revised List of Outstanding 
Issues to be addressed by the applicant in writing and if necessary during an oral explanation. 
The List of Outstanding Issues was sent to the applicant on 23 April 2004.  
The company submitted the responses to the revised CPMP List of Outstanding Issues on 12 
May 2004. 
The Rapporteur circulated the Rapporteurs’ Joint Review on the company’s responses to the 
revised List of Outstanding Issues to all CHMP members on 8 June 2004.   
In the margin of the CHMP meeting on 22 – 23 June 2004, an ad hoc expert meeting took place 
on 21 June 2004. During the CHMP meeting on 22 – 23 June 2004, it was decided that in the 
2/4 
EMEA 2004 
 
 
light of the outcome of the ad hoc expert meeting there was no longer any need for the applicant 
to address outstanding issues during an oral hearing before the CHMP. 
During  the  meeting  on  27  -29  July 2004, the CHMP  adopted  a report from the ad  hoc  expert 
meeting of 21 June 2004.   
The company submitted revised documents for consideration by CHMP on 7 July 2004. 
The Rapporteur circulated the Rapporteurs’ Joint Review on the revised documents on 16 July 
2004.  
During  the  meeting  on  27  –  29  July  2004  the  CHMP,  in  the  light  of  the  overall  revised  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation under exceptional circumstances to Xagrid on 29 July 2004. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 16 November 2004. 
• 
• 
• 
• 
• 
2. 
GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION 
1.  Manufacturing authorisation holder  
Manufacturers of the active substance 
•  Cambridge Major Laboratories Inc., North 115 West 19392 Edison Drive, Germantown, WI 
53022, United States 
•  Powdersize Inc., 20 Pacific Drive, Quakertown, PA 18951, United States 
Manufacturers of the finished product 
•  Mallinckrodt Inc., Main Plant and Office, Building 1, 58 Pearl Street, P.O. Box P, Hobart, NY 
13788, United States 
An inspection of this manufacturing site was carried out by the MCA on 3-4 October 2002. The 
findings of the inspection are in compliance with the Community Good Manufacturing Practice 
requirements. 
•  Wasdell Packaging Limited, Upper Mills Estate, Bristol Road, Stonehouse, Gloucestershire, GL10 
2BJ, United Kingdom 
Manufacturer responsible for import and batch release in the European Economic Area 
•  Wasdell Packaging Limited, Upper Mills Estate, Bristol Road, Stonehouse, Gloucestershire, GL10 
2BJ, United Kingdom 
Manufacturing authorisation issued on 11 January 1999 by the MCA.  
2. 
Conditions or restrictions regarding supply and use 
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product 
Characteristics, 4.2). 
Other conditions 
The holder of this marketing authorisation must inform the European Commission about the marketing 
plans for the medicinal product authorised by this decision. 
3/4 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
3. 
Specific obligations and/or follow-up measures of the Marketing Authorisation Holder  
Pursuant to article 13 (2) of Council Regulation (EEC) No 2309/93 and Part 4 G of the Annex I to 
Directive 2001/83/EC, the applicant agreed to provide, as requested by the CHMP, additional clinical 
data which will form the basis of a re-assessment of the benefit/risk ratio of Xagrid. In addition, the 
applicant will submit PSURs at 6-, 12-, 18-, 24-months, 3 years, 4 years and as part of the renewal 
application, as of the granting of the Commission Decision for Xagrid.  
In addition, the applicant agreed to submit to the EMEA, within a defined timeframe, further 
information requested by the CHMP on quality and pre-clinical aspects. 
4/4 
EMEA 2004 
 
